Advanced forced degradation technique for simultaneous estimation of azelnidipine and telmisartan implementing AQbD approach in its tablet dosage form
Keywords:
method development, azelnidipine, telmisartan, RP-HPLC, stability studiesAbstract
For simultaneous estimation of Azelnidipine and Telmisartan in pharmaceutical dosage form, a simple, rapid, precise and reproducible RP-HPLC method was developed. Separation was achieved on a Phenomanax Luna C18; 5 μm, 150 mm × 4.6 mm i.d. column using water and methanol 50: 50 (v/v) as mobile phase and detected at 256 nm using PDA detector. Azelnidipine and Telmisartan were exposed to thermal, photolytic, hydrolytic and oxidative stress conditions and stressed samples were analyzed by the proposed method. Linearity, precision, accuracy, specificity and robustness were studied as reported in the International Council for Harmonization guidelines. Linearity of the proposed method was in the range of 4-12 μg mL-1 (r2 = 0.998) for Azelnidipine and 20-60 μg mL-1 (r2 = 0.997) for Telmisartan. Limits of Detection were 1.041 μg mL-1 and 0.208 μg mL-1, while Limits of Quantitation were 3.155 μg mL-1 and 0.631 μg mL-1 for Azelnidipine and Telmisartan respectively. Degradation products produced as a result of stress studies did not interfere with the detection. The proposed stability studies method for simultaneous estimation was found to be specific, accurate and economical that could be applied for routine analysis of drugs in bulk and multi component formulations in quality control laboratories.
Downloads
References
Oparil, S., Acelajado, M. C., Bakris. G. L., Berlowitz, D. R., Cifkova, R., & Dominiczak, A. F. (2018). Hypertension. Nature Reviews Disease Primers, 4:18014.
Chen, B. L., Zhang, Y. Z., Luo, J. Q., & Zhang, W. (2015). Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. Therapeutics and clinical risk management, 11, 309.
Zhao, X., Wu, F., Jia, S., Qu, P., Li, H., Zhao, X., & Wang, M. (2010). Azelnidipine and amlodipine: a comparison of their effects and safety in a randomized double-blinded clinical trial in Chinese essential hypertensive patients. Clinical and Experimental Hypertension, 32(6), 372-376.
Watanabe, M., Hirano, T., Okamoto, S., Shiraishi, S., Tomiguchi, S., & Uchino, M. (2010). Azelnidipine, a long-acting calcium channel blocker, could control hypertension without decreasing cerebral blood flow in post-ischemic stroke patients. A 123I-IMP SPECT follow-up study. Hypertension Research, 33(1), 43-48.
Destro, M., Cagnoni, F., Dognini, G. P., Galimberti, V., Taietti, C., Cavalleri, C., & Galli, E. (2011). Telmisartan: just an antihypertensive agent? A literature review. Expert Opinion on Pharmacotherapy, 12(17), 2719-2735.
Suhas, D., Deepak, B., & Kavita, A. (2013). Review on pharmacovigilance study of telmisartan in hypertension patients. Asian Journal of Pharmacy and Clinical Research, 6(3), 17-20.
Wani, S. U. D., Gangadharappa, H. V., & Ashish, N. P. (2019). Formulation, development and characterization of drug delivery systems based telmisartan encapsulated in silk fibroin nanosphere’s. International Journal of Applied Pharmacy, 11, 247-54.
Galzerano, D., Capogrosso, C., Di Michele, S., Galzerano, A., Paparello, P., Lama, D., & Gaudio, C. (2010). New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vascular health and risk management, 6, 113.
Ayza, M. A., Zewdie, K. A., Tesfaye, B. A., Gebrekirstos, S. T., & Berhe, D. F. (2020). Anti-diabetic effect of telmisartan through its partial PPARγ-agonistic activity. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 3627.
Balakumar, P., K Bishnoi, H., & Mahadevan, N. (2012). Telmisartan in the management of diabetic nephropathy: a contemporary view. Current diabetes reviews, 8(3), 183-190.
Patel, N., & Patel, J. (2012). Simultaneous determination of azelnidipine and olmesartan medoxomil by first derivative spectrophotometric method. Der Pharmacia Lettre, 4(4).
Goparaju, G., & Kaushal, G. (2014). Significance of Stability-indicating LC methods in pharmaceuticals. Austin Chromatography, 1(1), 1-2.
PANDYA, C. P., & RAJPUT, S. J. (2018). Development and validation of stability indicating method RP-HPLC method of acotiamide. International Journal of Pharmacy and Pharmaceutical Sciences, 10, 1-8.
Rode, D. M. & Rao, N. N. (2019). A review on development and validation of stability-indicating HPLC methods for the analysis of acidic drugs. International Journal of Current Pharmaceutical Research, 11:22-33.
Sabir, A. M., Moloy, M. & Bhasin, P. S. (2015). HPLC method development and validation: a review. International Research Journal of Pharmacy, 4:39-46.
Locatelli, M., Melucci, D., Carlucci, G., & Locatelli, C. (2012). Recent HPLC strategies to improve sensitivity and selectivity for the analysis of complex matrices. Instrumentation Science & Technology, 40(2-3), 112-137.
Ravisankar, P., Navya, C. N., Pravallika, D., & Sri, D. N. (2015). A review on step-by-step analytical method validation. IOSR Journal of Pharmacy, 5(10), 7-19.
Betz, J. M., Brown, P. N., & Roman, M. C. (2011). Accuracy, precision, and reliability of chemical measurements in natural products research. Fitoterapia, 82(1), 44-52.
Kawabata, K., & Urasaki, Y. (2006). Simultaneous determination of azelnidipine and two metabolites in human plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B, 844(1), 45-52.
Ding, L., Chen, Y., Yang, L., & Wen, A. (2007). Determination of palonosetron in human plasma by liquid chromatography–electrospray ionization-mass spectrometry. Journal of Pharmaceutical and Biomedical analysis, 44(2), 575-580.
Jia, J., Nan, F., Liang, M. Z., Yu, Q., Qin, Y. P., & Xiang, J. (2010). Determination and pharmacokinetics of azelnidipine in human plasma by HPLC-MS-MS. Chinese Journal of Hospital Pharmacy, 24.
Ponnekanti, K., & Sunitha, K. (2021). Development of hplc stability demonstrating methodology for quantifying azelnidipine and telmisartan in tablets and bulk types: validation following ich directives. International Journal of Applied Pharmaceutics, 298-305.
Kumar, M., Chandra, U., Garg, A. & Gupta, P. (2021). A Stability Indicating RP-HPLC Method Validation For Simultaneous Estimation Of Azelnidipine And Telmisartan In A Fixed-Dose Combination, International Journal of Pharmaceutical Sciences and Drug Research. 2021; 13(3):288-294.
ICH Harmonised Tripartite Guideline: Validation of Analytical Procedures: Text and Methodology Q2 (R1), International Conference on Harmonisation: Geneva, 2005.
ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A (R2), International Conference on Harmonisation: Geneva, 2003.
ICH Harmonised Tripartite Guideline: Photostability testing of New Drug Substances and Products Q1B, International Conference on Harmonisation: Geneva, 2003.
Ferreira, S. L., Caires, A. O., Borges, T. D. S., Lima, A. M., Silva, L. O., & dos Santos, W. N. (2017). Robustness evaluation in analytical methods optimized using experimental designs. Microchemical Journal, 131, 163-169.
Shah, B. P., Jain, S., Prajapati, K. K. & Mansuri, N. Y. (2012). Stability Indicating HPLC method development: a review. International Journal of Pharmaceutical Sciences and Research, 3:2978-88.
Nadpara, N. P., Thumar, R. V., Kalola, V. N., & Patel, P. B. (2012). Quality by design (QBD): A complete review. International Journal of Pharmaceutical Sciences Review and Research, 17(2), 20-8.
Patil, A. S., &Pethe, A. M. (2013). Quality by Design (QbD): A new concept for development of quality pharmaceuticals. International journal of pharmaceutical quality assurance, 4(2), 13-19.
Roy, S. (2012). Quality by design: A holistic concept of building quality in pharmaceuticals. International Journal of Pharmaceutical and Biomedical Research, 3(2), 100-108.
Bhutani, H., Kurmi, M., Singh, S., Beg, S., & Singh, B. (2004). Quality by design (QbD) in analytical sciences: an overview. Quality Assurance, 3, 39.
Bajaj, M., & Nanda, S. (2015). Analytical Quality by Design (AQbD), New paradigm for analytical method development. International Journal of Development Research, 5(2): 3589-99.
Garud, S. S., Derle, D. V., &Derle, N. D. (2013). A Role of models in quality by design (QbD) paradigm-a review. International Journal of Biopharmaceutics, 4(3), 80-89.
Jain, S. (2016). Quality by Design: A comprehensive understanding of implementation and challenges in pharmaceuticals development. International Journal of Pharmacy and Pharmaceutical Sciences, 6(1): 29-35.
Kumar, S. (2022). A quest for sustainium (sustainability Premium): review of sustainable bonds. Academy of Accounting and Financial Studies Journal, Vol. 26, no.2, pp. 1-18
Allugunti V.R (2022). A machine learning model for skin disease classification using convolution neural network. International Journal of Computing, Programming and Database Management 3(1), 141-147
Allugunti V.R (2022). Breast cancer detection based on thermographic images using machine learning and deep learning algorithms. International Journal of Engineering in Computer Science 4(1), 49-56
Shah, A. D., & Patel, C. N. (2014). Implementation of QbD approach to the RP-HPLC method development and validation of roflumilast in bulk and tablet dosage form: an application in degradation study. World Journal of Pharmacy and Pharmaceutical Sciences, 3(6), 2281-2307.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). The COVID-19 pandemic. International Journal of Health Sciences, 5(2), vi-ix. https://doi.org/10.53730/ijhs.v5n2.2937
Khidoyatova, M. R., Kayumov, U. K., Inoyatova, F. K., Fozilov, K. G., Khamidullaeva, G. A., & Eshpulatov, A. S. (2022). Clinical status of patients with coronary artery disease post COVID-19. International Journal of Health & Medical Sciences, 5(1), 137-144. https://doi.org/10.21744/ijhms.v5n1.1858
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.








